Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 37 | 2024 | 2926 | 4.050 |
Why?
|
Immunotherapy | 20 | 2024 | 4746 | 1.990 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2024 | 4049 | 1.960 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2021 | 262 | 1.870 |
Why?
|
Oropharyngeal Neoplasms | 9 | 2023 | 492 | 1.570 |
Why?
|
Radiotherapy | 7 | 2023 | 1491 | 1.490 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2022 | 781 | 1.350 |
Why?
|
Neoplasms | 23 | 2024 | 22344 | 1.230 |
Why?
|
Papillomavirus Infections | 9 | 2023 | 1637 | 1.070 |
Why?
|
Combined Modality Therapy | 17 | 2024 | 8525 | 0.950 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2024 | 9378 | 0.930 |
Why?
|
Carcinoma, Merkel Cell | 4 | 2024 | 328 | 0.840 |
Why?
|
Mouth Neoplasms | 4 | 2022 | 595 | 0.780 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5388 | 0.770 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11859 | 0.740 |
Why?
|
Neoadjuvant Therapy | 8 | 2024 | 2897 | 0.670 |
Why?
|
Neoplasm Metastasis | 11 | 2022 | 4887 | 0.650 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 93 | 0.620 |
Why?
|
Melanoma | 9 | 2021 | 5695 | 0.610 |
Why?
|
Radiation Tolerance | 2 | 2023 | 475 | 0.610 |
Why?
|
Medical Futility | 1 | 2019 | 136 | 0.590 |
Why?
|
Skin Neoplasms | 9 | 2024 | 5836 | 0.590 |
Why?
|
Neck | 1 | 2022 | 735 | 0.580 |
Why?
|
Radiotherapy Dosage | 9 | 2022 | 2863 | 0.580 |
Why?
|
Peer Review, Health Care | 1 | 2017 | 73 | 0.550 |
Why?
|
Head | 1 | 2022 | 926 | 0.540 |
Why?
|
Radiation Oncology | 3 | 2017 | 568 | 0.540 |
Why?
|
Lymphopenia | 1 | 2018 | 298 | 0.510 |
Why?
|
Salivary Gland Neoplasms | 3 | 2020 | 306 | 0.500 |
Why?
|
Lung Neoplasms | 7 | 2024 | 13483 | 0.500 |
Why?
|
Papillomaviridae | 8 | 2022 | 1137 | 0.490 |
Why?
|
Immunomodulation | 1 | 2019 | 548 | 0.470 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13635 | 0.470 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 3942 | 0.460 |
Why?
|
Carcinoma, Basal Cell | 3 | 2024 | 565 | 0.450 |
Why?
|
Humans | 117 | 2024 | 766117 | 0.450 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2015 | 347 | 0.440 |
Why?
|
Immunocompromised Host | 1 | 2019 | 865 | 0.430 |
Why?
|
Cancer Vaccines | 2 | 2011 | 1042 | 0.430 |
Why?
|
Cookbooks as Topic | 1 | 2012 | 1 | 0.420 |
Why?
|
Retrospective Studies | 33 | 2024 | 81565 | 0.420 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2022 | 1642 | 0.420 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1105 | 0.410 |
Why?
|
Radiation Injuries | 4 | 2021 | 1181 | 0.400 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9237 | 0.390 |
Why?
|
Saliva | 1 | 2017 | 852 | 0.390 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2046 | 0.380 |
Why?
|
Neoplasm Staging | 13 | 2024 | 11200 | 0.370 |
Why?
|
Endoribonucleases | 1 | 2013 | 230 | 0.360 |
Why?
|
Brain Neoplasms | 7 | 2021 | 9065 | 0.360 |
Why?
|
Immunotherapy, Active | 1 | 2010 | 58 | 0.360 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2020 | 1777 | 0.350 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2824 | 0.350 |
Why?
|
Middle Aged | 51 | 2024 | 223083 | 0.350 |
Why?
|
Aged | 44 | 2024 | 171219 | 0.340 |
Why?
|
Carcinoma | 2 | 2023 | 2313 | 0.330 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2022 | 102 | 0.330 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 282 | 0.320 |
Why?
|
Radiosurgery | 4 | 2020 | 1328 | 0.320 |
Why?
|
Palliative Care | 3 | 2020 | 3639 | 0.320 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 495 | 0.300 |
Why?
|
Male | 56 | 2024 | 363935 | 0.300 |
Why?
|
Immunophenotyping | 3 | 2018 | 1865 | 0.300 |
Why?
|
Food | 1 | 2012 | 764 | 0.290 |
Why?
|
Aged, 80 and over | 25 | 2024 | 59515 | 0.290 |
Why?
|
Survival Analysis | 9 | 2021 | 10087 | 0.290 |
Why?
|
Appointments and Schedules | 1 | 2011 | 441 | 0.290 |
Why?
|
Pneumonia | 1 | 2019 | 2159 | 0.280 |
Why?
|
Patient Selection | 2 | 2021 | 4249 | 0.280 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 3594 | 0.270 |
Why?
|
Female | 52 | 2024 | 396233 | 0.260 |
Why?
|
Pyrroles | 1 | 2012 | 1120 | 0.250 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1471 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6506 | 0.240 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3214 | 0.240 |
Why?
|
Carcinoma, Renal Cell | 2 | 2018 | 3186 | 0.240 |
Why?
|
Neovascularization, Pathologic | 2 | 2011 | 2627 | 0.230 |
Why?
|
Tumor Burden | 2 | 2021 | 1889 | 0.230 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6961 | 0.220 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12529 | 0.220 |
Why?
|
Indoles | 1 | 2012 | 1833 | 0.220 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1383 | 0.220 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1056 | 0.220 |
Why?
|
Research Design | 1 | 2019 | 6206 | 0.220 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2744 | 0.210 |
Why?
|
Radiation Dosage | 2 | 2022 | 1945 | 0.210 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2024 | 4649 | 0.210 |
Why?
|
Organs at Risk | 2 | 2022 | 352 | 0.210 |
Why?
|
Pregnancy Proteins | 1 | 2004 | 222 | 0.200 |
Why?
|
Prognosis | 12 | 2024 | 29912 | 0.200 |
Why?
|
Dermatitis | 2 | 2017 | 201 | 0.200 |
Why?
|
Prostatic Neoplasms | 5 | 2020 | 11094 | 0.190 |
Why?
|
Gadolinium | 2 | 2024 | 966 | 0.190 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9527 | 0.180 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 79 | 0.180 |
Why?
|
Immune System | 2 | 2018 | 799 | 0.180 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6840 | 0.180 |
Why?
|
Prostatectomy | 3 | 2014 | 1786 | 0.180 |
Why?
|
Parotid Gland | 1 | 2022 | 178 | 0.180 |
Why?
|
Treatment Outcome | 16 | 2024 | 65219 | 0.180 |
Why?
|
Kidney Neoplasms | 2 | 2018 | 4282 | 0.180 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 80 | 0.180 |
Why?
|
Immunologic Factors | 2 | 2021 | 1592 | 0.180 |
Why?
|
Cisplatin | 3 | 2024 | 1654 | 0.180 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8038 | 0.170 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3360 | 0.170 |
Why?
|
Antibody Formation | 2 | 2016 | 1392 | 0.160 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2021 | 287 | 0.160 |
Why?
|
Cytokines | 4 | 2019 | 7426 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2021 | 211 | 0.160 |
Why?
|
Adult | 29 | 2024 | 223139 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2354 | 0.150 |
Why?
|
Nucleic Acid Denaturation | 1 | 2018 | 111 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20700 | 0.150 |
Why?
|
Anti-Infective Agents, Local | 1 | 2020 | 246 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 378 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 514 | 0.150 |
Why?
|
Survival Rate | 4 | 2018 | 12827 | 0.150 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6545 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5336 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2010 | 3501 | 0.140 |
Why?
|
Radiation Protection | 1 | 2021 | 424 | 0.140 |
Why?
|
Stomatitis | 1 | 2020 | 270 | 0.140 |
Why?
|
Mouth | 1 | 2020 | 383 | 0.140 |
Why?
|
Larynx | 1 | 2022 | 492 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 249 | 0.140 |
Why?
|
Polymerase Chain Reaction | 3 | 2024 | 6059 | 0.140 |
Why?
|
Quality Assurance, Health Care | 2 | 2017 | 2171 | 0.140 |
Why?
|
Phantoms, Imaging | 2 | 2022 | 2474 | 0.140 |
Why?
|
Osteoradionecrosis | 1 | 2017 | 51 | 0.140 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.130 |
Why?
|
Epirubicin | 1 | 2016 | 82 | 0.130 |
Why?
|
Lymphocyte Count | 1 | 2018 | 791 | 0.130 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 167 | 0.130 |
Why?
|
Gastrointestinal Tract | 1 | 2021 | 834 | 0.120 |
Why?
|
Prospective Studies | 8 | 2021 | 54812 | 0.120 |
Why?
|
Mucositis | 2 | 2019 | 107 | 0.120 |
Why?
|
Tooth Diseases | 1 | 2015 | 73 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 384 | 0.120 |
Why?
|
Signal Transduction | 3 | 2015 | 23605 | 0.120 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12061 | 0.120 |
Why?
|
Chemokines | 2 | 2018 | 959 | 0.120 |
Why?
|
Nanoparticles | 2 | 2024 | 1966 | 0.110 |
Why?
|
Ecosystem | 1 | 2018 | 489 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1060 | 0.110 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2029 | 0.110 |
Why?
|
Drug Carriers | 1 | 2018 | 701 | 0.110 |
Why?
|
Breast Neoplasms | 3 | 2020 | 21074 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1916 | 0.110 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39243 | 0.100 |
Why?
|
Lymph Nodes | 3 | 2023 | 3456 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1086 | 0.100 |
Why?
|
SEER Program | 4 | 2020 | 1443 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1319 | 0.100 |
Why?
|
Information Dissemination | 1 | 2021 | 1142 | 0.100 |
Why?
|
Killer Cells, Natural | 2 | 2018 | 2206 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3159 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3546 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 4423 | 0.090 |
Why?
|
Computational Biology | 1 | 2004 | 3565 | 0.090 |
Why?
|
Drug Therapy | 1 | 2015 | 504 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.090 |
Why?
|
Medical Oncology | 1 | 2023 | 2339 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2890 | 0.090 |
Why?
|
Interferons | 1 | 2015 | 714 | 0.090 |
Why?
|
Gastrectomy | 1 | 2016 | 693 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1433 | 0.090 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1009 | 0.090 |
Why?
|
Transcription, Genetic | 2 | 2004 | 7600 | 0.090 |
Why?
|
Xerostomia | 1 | 2010 | 94 | 0.090 |
Why?
|
Angiopoietin-1 | 1 | 2010 | 132 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1557 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1890 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 183 | 0.090 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 91 | 0.090 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 637 | 0.080 |
Why?
|
Angiopoietin-2 | 1 | 2010 | 186 | 0.080 |
Why?
|
Esophagitis | 1 | 2010 | 163 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2016 | 1155 | 0.080 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10260 | 0.080 |
Why?
|
Young Adult | 9 | 2021 | 59868 | 0.080 |
Why?
|
Androgen Antagonists | 2 | 2020 | 1411 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1394 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 878 | 0.080 |
Why?
|
Cytoskeletal Proteins | 2 | 2005 | 1322 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 3249 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10380 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2702 | 0.080 |
Why?
|
Colitis | 1 | 2017 | 1240 | 0.080 |
Why?
|
Apoptosis | 1 | 2024 | 9508 | 0.070 |
Why?
|
Gene Library | 1 | 2010 | 1066 | 0.070 |
Why?
|
Recurrence | 1 | 2020 | 8494 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1765 | 0.070 |
Why?
|
Risk Factors | 6 | 2023 | 74857 | 0.070 |
Why?
|
Carboplatin | 1 | 2010 | 787 | 0.070 |
Why?
|
Melanoma, Experimental | 1 | 2010 | 555 | 0.070 |
Why?
|
Cohort Studies | 6 | 2024 | 41684 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1926 | 0.070 |
Why?
|
Animals | 10 | 2022 | 168800 | 0.070 |
Why?
|
Incidental Findings | 1 | 2011 | 698 | 0.070 |
Why?
|
Mucous Membrane | 2 | 2021 | 658 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 608 | 0.070 |
Why?
|
beta Catenin | 3 | 2006 | 1047 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2011 | 965 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40108 | 0.060 |
Why?
|
Glioblastoma | 1 | 2021 | 3458 | 0.060 |
Why?
|
Neutrophils | 1 | 2018 | 3771 | 0.060 |
Why?
|
Developing Countries | 1 | 2017 | 2914 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2023 | 20137 | 0.060 |
Why?
|
Prostate | 1 | 2013 | 1758 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1535 | 0.060 |
Why?
|
Trans-Activators | 2 | 2005 | 2849 | 0.060 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2006 | 414 | 0.060 |
Why?
|
Inflammation | 2 | 2015 | 10860 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5926 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 24276 | 0.060 |
Why?
|
Patient Preference | 1 | 2011 | 947 | 0.060 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2024 | 201 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2011 | 3602 | 0.050 |
Why?
|
Umbilical Veins | 1 | 2004 | 422 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1727 | 0.050 |
Why?
|
Philadelphia | 1 | 2023 | 271 | 0.050 |
Why?
|
X-Rays | 1 | 2024 | 309 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2013 | 3227 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2689 | 0.050 |
Why?
|
Capillary Permeability | 1 | 2006 | 770 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11035 | 0.050 |
Why?
|
Logistic Models | 1 | 2017 | 13273 | 0.050 |
Why?
|
Genotype | 2 | 2016 | 13028 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8612 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7474 | 0.050 |
Why?
|
Culture Media | 1 | 2004 | 889 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4853 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 172 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3853 | 0.050 |
Why?
|
Genetic Variation | 1 | 2016 | 6612 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36548 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10811 | 0.040 |
Why?
|
Mice | 5 | 2022 | 81839 | 0.040 |
Why?
|
Endothelium | 1 | 2003 | 768 | 0.040 |
Why?
|
Antigens, CD | 1 | 2010 | 4025 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2024 | 2271 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2593 | 0.040 |
Why?
|
Bandages | 1 | 2020 | 270 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 419 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 152 | 0.040 |
Why?
|
Mohs Surgery | 1 | 2020 | 217 | 0.040 |
Why?
|
Algorithms | 2 | 2023 | 14066 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2018 | 355 | 0.040 |
Why?
|
Disease Progression | 3 | 2020 | 13616 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 16040 | 0.030 |
Why?
|
Jaw | 1 | 2017 | 95 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 13085 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 895 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 870 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2018 | 392 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 427 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1614 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27177 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7424 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2227 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2020 | 1152 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1273 | 0.030 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 325 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1820 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 449 | 0.030 |
Why?
|
United States | 3 | 2024 | 72920 | 0.030 |
Why?
|
Workflow | 1 | 2018 | 859 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2006 | 3586 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2010 | 6363 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 516 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 702 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1315 | 0.020 |
Why?
|
HIV Infections | 1 | 2019 | 17535 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2018 | 5881 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2006 | 18967 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2020 | 2242 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 1544 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1852 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21513 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5986 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1950 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4335 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2021 | 8113 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3684 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12426 | 0.020 |
Why?
|
Wound Healing | 1 | 2020 | 2795 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4112 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2048 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7193 | 0.020 |
Why?
|
Proteins | 1 | 2004 | 5995 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2054 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5330 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 911 | 0.020 |
Why?
|
Blotting, Western | 2 | 2006 | 5020 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5503 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3955 | 0.020 |
Why?
|
Histamine Agents | 1 | 2006 | 3 | 0.020 |
Why?
|
Receptors, Histamine | 1 | 2006 | 23 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2210 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6768 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 2463 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11906 | 0.020 |
Why?
|
gamma Catenin | 1 | 2005 | 45 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4408 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2946 | 0.020 |
Why?
|
Desmoplakins | 1 | 2005 | 64 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10614 | 0.010 |
Why?
|
Phosphoserine | 1 | 2005 | 203 | 0.010 |
Why?
|
Rats | 1 | 2021 | 23717 | 0.010 |
Why?
|
Base Sequence | 1 | 2016 | 12405 | 0.010 |
Why?
|
Alleles | 1 | 2016 | 6892 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2332 | 0.010 |
Why?
|
Histamine | 1 | 2006 | 495 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2022 | 11642 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3849 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3665 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 812 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13468 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2006 | 2469 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8347 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18321 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3530 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26290 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 13046 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2005 | 1494 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
Exons | 1 | 2005 | 2393 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15403 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9601 | 0.010 |
Why?
|
Cytoplasm | 1 | 2003 | 1498 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 2455 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4863 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2006 | 2877 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2003 | 3089 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2003 | 2627 | 0.010 |
Why?
|
Actins | 1 | 2003 | 2061 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4466 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6493 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8292 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5739 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 30209 | 0.010 |
Why?
|
Protein Binding | 1 | 2005 | 9301 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15546 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 9445 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2003 | 14456 | 0.000 |
Why?
|
Adolescent | 1 | 2015 | 88819 | 0.000 |
Why?
|
Lung | 1 | 2003 | 10063 | 0.000 |
Why?
|